ATOS Quote, Financials, Valuation and Earnings

Celldex Therapeutics, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of -7753.43%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.

Atossa Therapeutics, Inc. has a consensus price target of $5.69, signalling upside risk potential of 648.85%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.14 which suggests that it could grow by 79.54%. Given that Atossa Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..

Atossa Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.281%.

Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Celldex Therapeutics, Inc. quarterly revenues of --. Atossa Therapeutics, Inc.'s net income of -$8.7M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 755.79x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiora Pharmaceuticals, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of 84.08%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.

Atossa Therapeutics, Inc. has a consensus price target of $5.69, signalling upside risk potential of 648.85%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 423.81%. Given that Atossa Therapeutics, Inc. has higher upside potential than Kiora Pharmaceuticals, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Kiora Pharmaceuticals, Inc..

Atossa Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.753, suggesting its less volatile than the S&P 500 by 175.254%.

Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of -735.19%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Atossa Therapeutics, Inc. has a consensus price target of $5.69, signalling upside risk potential of 648.85%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 147.59%. Given that Atossa Therapeutics, Inc. has higher upside potential than Intellia Therapeutics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Intellia Therapeutics, Inc..

Atossa Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Atossa Therapeutics, Inc.'s net income of -$8.7M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 16.51x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -- compared to Atossa Therapeutics, Inc.'s net margin of 7.29%. Atossa Therapeutics, Inc.'s return on equity of -47.46% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Atossa Therapeutics, Inc. has a consensus price target of $5.69, signalling upside risk potential of 648.85%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that Atossa Therapeutics, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Atossa Therapeutics, Inc. is more attractive than Phibro Animal Health Corp..

Atossa Therapeutics, Inc. has a beta of 0.950, which suggesting that the stock is 4.956% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Atossa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. Atossa Therapeutics, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Atossa Therapeutics, Inc. quarterly revenues are --, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Atossa Therapeutics, Inc.'s net income of -$8.7M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Atossa Therapeutics, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atossa Therapeutics, Inc. is -- versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.